Dynamic MapReport

World News   USA   California   Bay Area   San Francisco   North San Mateo County   South SF   Genentech (120)
Genentech Timeline Sunday, June 17 Bookmark and Share     Author
Search Bay Area News Atlas:
World News (13) USA (336) California (187) Bay Area (13) San Francisco (2215) North San Mateo County (177) South SF (135) Genentech (120)
2014 (1) 2013 (1) 2011 (1) 2010 (4) 2009 (13) 2008 (11) 2007 (3) 2006 (8) 2005 (5) 2004 (5) 2003 (5) 2002 (2) 2001 (1)
Avastin (14) Herceptin (3) Lucentis (2)
Genentech on Wikipedia Genentech on Web

Chart Time by Topic
Avastin (14)   Roche (16)   South SF Merger and Acquisition (19)   Cancer (64)   South SF Bio Tech (40)
Recent Summary.     Click for More >
No news/event found


Science & Education Main Event: FDA clears d...
Genentech on Google Map

B. 2014-07-02 Genentech to buy Seragon Pharmaceuticals Genentech
C. 2013-10-14 Genentech invests $285 million in biotech in state Genentech
D. 2010-11-18 Genentech cutting 450 jobs in South SF Genentech
4. 2010-07-20 Panel doesn't back Avastin for cancer Genentech
F. 2010-07-02 Avastin delays ovarian cancer Genentech
6. 2010-01-09 FDA Approves Actemra Arthritis Drug Genentech
2009-08-02 FDA clears drug for kidney cancer Genentech
I. 2009-07-09 Axe falls at Genentech Genentech



     * Time by Topic
Genentech, 21st Century, Time by Topic
Time Bio Tech Merger and Acquisition Earnings Science & Education
2014
Genentech to buy Seragon Pharmaceuticals
Genentech to buy Seragon Pharmaceuticals
Earnings
2014 2014
Earnings
Science & Education
2014 2014
Science & Education
2011
Bio Tech
2011 2011
Bio Tech
Merger and Acquisition
2011 2011
Merger and Acquisition
Earnings
2011 2011
Earnings
Science & Education
2011 2011
Science & Education
2010
Panel doesn't back Avastin for cancer
Avastin delays ovarian cancer
Merger and Acquisition
2010 2010
Merger and Acquisition
Earnings
2010 2010
Earnings
Panel doesn't back Avastin for cancer
FDA Approves Actemra Arthritis Drug
2009
FDA clears drug for kidney cancer
Axe falls at Genentech
Drug Raptiva pulled from market
Roche to take over Genentech for $47B
Roche-Genentech deal called close
Roche raises bid for Genentech
Roche launches $86.50-a-share bid
Roche revives takeover bid of Genentech
Axe falls at Genentech
Big leadership changes at Genentech
Roche to take over Genentech for $47B
Roche-Genentech deal called close
Roche raises bid for Genentech
Roche launches $86.50-a-share bid
Roche revives takeover bid of Genentech
Earnings
2009 2009
Earnings
Roche touts Herceptin in stomach cancers
2008
Avastin linked to higher risk of clots
Retention plan to cost $371 million
Genentech rejects Roche's $43.7b bid
Roche Offers $44B For Remaining Shares
Bad news on cancer drug Rituxan
Court slashes $200 million from judgment
FDA Clears Avastin for Breast Cancer
Retention plan to cost $371 million
Genentech rejects Roche's $43.7b bid
Panel to ponder Roche takeover offer
4Q Profit Rises 6 Percent
Avastin linked to higher risk of clots
2007
FDA Panel Rejects Avastin, stock drops
3Q Profit Up 21 % On Cancer Drug Sales
Merger and Acquisition
2007 2007
Merger and Acquisition
3Q Profit Up 21 % On Cancer Drug Sales
4Q Earnings Soar 75%
Science & Education
2007 2007
Science & Education
2006
Genentech to acquire partner Tanox
Cancer drug review extended
Tony Blair Visits Genentech Headquarters
2Q Profit Soars to $531 Million
FDA approves blindness drug
Cancer Drug Trials Scaled Back
Genentech to acquire partner Tanox
2Q Profit Soars to $531 Million
Profit climbs by 48% in first quarter
Up 64% in quarter after good year
Cancer Drug Trials Scaled Back
2005
Profits Soar 73% in 2Q
Avastin helps those with breast cancer
Biotech giant's profit up 61%
4th best place to work for in U.S.
Merger and Acquisition
2005 2005
Merger and Acquisition
Profits Soar 73% in 2Q
Biotech giant's profit up 61%
Profit surges, misses expectations by 1c
Avastin helps those with breast cancer
2004
Avastin helps sickest patients
Profits surge on drug sales
Profits surge on brisk cancer drug sales
FDA approves cancer fighter Avastin
Merger and Acquisition
2004 2004
Merger and Acquisition
Profits surge on drug sales
Profits surge on brisk cancer drug sales
Profits surge on strong drug sales
Avastin helps sickest patients
2003
Biotech titan posts higher profits
Encouraging results with cancer drug
Merger and Acquisition
2003 2003
Merger and Acquisition
Biotech titan posts higher profits
Science & Education
2003 2003
Science & Education
2002
Big patent win vs. Chiron
Merger and Acquisition
2002 2002
Merger and Acquisition
Earnings
2002 2002
Earnings
Science & Education
2002 2002
Science & Education

     *
Time by Topic


Add a favorite (file a bookmark) to Genentech News Timeline

Please send feedback to: support@mapreport.com

Advertise on Genentech Page

Dynamic MapReport
Legend  

XML

Details:

Genentech to buy Seragon Pharmaceuticals  Genentech, which is part of Roche, will pay for a San Diego company developing treatments for the most common kind of breast cancer Apple names Levinson non-exec chair Panel doesn't back Avastin for cancer  The drug, which was developed by Roche's Genentech unit, failed to win a U.S. panel's backing for continued sales as a treatment for breast ... Avastin delays ovarian cancer  A late-stage clinical trial showed that Genentech's drug Avastin can delay the progression of recently-diagnosed ovarian cancer FDA Approves Actemra Arthritis Drug  Biotechnology company says the U.S. Food and Drug Administration has approved its new drug to treat rheumatoid arthritis FDA clears drug for kidney cancer


year 2014 Top ^

Jul.2


year 2013 Top ^

Oct.14  Genentech invests $285 million in biotech in state


year 2011 Top ^

Nov.15


year 2010 Top ^

Nov.18  Genentech cutting 450 jobs in South SF
Jul.20
Jul.2
Jan.9


year 2009 Top ^

Aug.2
  Food and Drug Administration approved its cancer treatment Avastin for a new use, marking the sixth approval for the blockbuster drug
Jul.9 Axe falls at Genentech
  Anxiety rippled through Genentech as Roche began to cut rank-and-file jobs as it folds the South SF biotech firm into its global operations
Apr.15 Big leadership changes at Genentech Apr.8 Drug Raptiva pulled from market  The unit of drugmaker Roch is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection Mar.26 Roche completes purchase of Genentech Mar.19 Roche touts Herceptin in stomach cancers Mar.12 Roche to take over Genentech for $47B
  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
Mar.9 Roche-Genentech deal called close  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal Mar.6 Roche raises bid for Genentech  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent Mar.3 Genentech replies to hostile Roche bid Feb.9 Roche launches $86.50-a-share bid  Swiss drugmaker officially launched its $42 billion hostile offer for the 44% of Genentech Inc. it doesn't already own Feb.6 Roche CEO: Offer for Genentech fair deal Jan.30 Roche revives takeover bid of Genentech  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Nov.18 Avastin linked to higher risk of clots
  A team of university researchers: Blockbuster cancer drug is linked to a significantly increased risk of blood clots in the veins Aug.21 Retention plan to cost $371 million
Aug.17 Recruiters eye Genentech employees Aug.13 Genentech rejects Roche's $43.7b bid  Biotechnology giant rejected a buyout offer from its majority owner Roche but said it is open to a higher takeover bid Jul.31 Shareholders sue to halt Roche buyout Jul.25 Panel to ponder Roche takeover offer Jul.21 Roche Offers $44B For Remaining Shares  Roche Holding, which already owns 55.9%, was offering $43.7 billion to take over the remaining shares of Genentech Apr.30 Bad news on cancer drug Rituxan  Shares in Genentech sagged, after the company said Rituxan failed to curb symptoms of the debilitating autoimmune disorder Apr.24 Court slashes $200 million from judgment  The company has been ordered to pay $500 million to a Southern California hospital for failing to pay royalties Feb.22 FDA Clears Avastin for Breast Cancer
  A Genentech drug received federal approval, a surprise decision
Jan.14 4Q Profit Rises 6 Percent

year 2007 Top ^

Dec.5 FDA Panel Rejects Avastin, stock drops  Shares dropped nearly 9% after a panel of medical experts said FDA should deny approval of the company's blockbuster drug Oct.16 3Q Profit Up 21 % On Cancer Drug Sales
Jan.10 4Q Earnings Soar 75%

year 2006 Top ^

Nov.11 Genentech to acquire partner Tanox
Aug.12 Cancer drug review extended Jul.31 Tony Blair Visits Genentech Headquarters  Heavy hitters from biotech firms sat down for an extraordinary talk with British Prime Minister Jul.11 2Q Profit Soars to $531 Million Jul.1 FDA approves blindness drug Apr.12 Profit climbs by 48% in first quarter Feb.13 Cancer Drug Trials Scaled Back  Avastin only targets cancer, and leaves healthy cells alone Jan.11 Up 64% in quarter after good year

year 2005 Top ^

Jul.11 Profits Soar 73% in 2Q  The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents Apr.16 Avastin helps those with breast cancer
Apr.12 Biotech giant's profit up 61% Jan.10 4th best place to work for in U.S. Profit surges, misses expectations by 1c

year 2004 Top ^

Nov.29 Avastin helps sickest patients
Oct.6 Profits surge on drug sales Apr.7 Profits surge on brisk cancer drug sales Feb.26 FDA approves cancer fighter Avastin Jan.14  Profits surge on strong drug sales

year 2003 Top ^

Oct.8  Biotech titan posts higher profits Aug.15  Firm: Genentech refuses to share profits May.19 Encouraging results with cancer drug
  Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45%
May.12  Arthritis drug fails key experiment May.9  Janitors will get health insurance

year 2002 Top ^

Sep.10  Stock plummets 9.7% Sep.7  Big patent win vs. Chiron

year 2001 Top ^

Oct.11  $400 million suit against Genentech